Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 4/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815652 | 0.85 | FYN (0.48) | PDGFRBPDGFRAFYNCLK4DYRK1A | |
| SCHEMBL24453555 | 0.81 | CLK4 (0.50) | PDGFRBPDGFRAFYNCLK4DYRK1A | |
| SCHEMBL2406367 | 0.76 | DYRK1A (0.54) | PDGFRBPDGFRAFYNCLK4DYRK1A | |
| SCHEMBL24453557 | 0.76 | CLK4 (0.50) | PDGFRBPDGFRAFYNCLK4DYRK1A | |
| SCHEMBL14815493 | 0.75 | CYP17A1 (0.72) | CYP17A1ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL3265693 | 0.73 | ABL1 (0.55) | PDGFRBPDGFRAFYNCLK4DYRK1A | |
| SCHEMBL13575386 | 0.73 | HSD17B1 (0.67) | PDGFRBPDGFRAFYNCLK4DYRK1A | |
| SCHEMBL11153370 | 0.72 | NPC1 (0.67) | PDGFRBPDGFRAFYNCLK4DYRK1A | |
| SCHEMBL12486978 | 0.72 | MAP4K4 (0.62) | PDGFRBPDGFRAFYNCLK4DYRK1A | |
| SCHEMBL2239434 | 0.71 | FYN (0.51) | PDGFRBPDGFRAFYNCLK4DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760854-B1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ASANA BIOSCIENCES LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2760854-B1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ASANA BIOSCIENCES LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9199975-B2 | Biaryl imidazole derivatives for regulating CYP17 | ASANA BIOSCIENCES, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199975-B2 | Biaryl imidazole derivatives for regulating CYP17 | ASANA BIOSCIENCES, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199975-B2 | Biaryl imidazole derivatives for regulating CYP17 | ASANA BIOSCIENCES, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2760854-A1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | Endo Pharmaceuticals Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049565-A1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049565-A1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085164-A1 | Imidazole Derivatives | CYP17A1, CYP2A7, CYP11B1 | PDGFRB 2474/4885PDGFRA 1912/4885FYN 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.